We are live on ! Find out more
LAB icon

Standard BioTools
LAB

99 hedge funds and large institutions have $422M invested in Standard BioTools in 2018 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 39 increasing their positions, 18 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,594% more call options, than puts

Call options by funds: $288K | Put options by funds: $17K

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

182% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 11

117% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 18

45% more capital invested

Capital invested by funds: $291M → $422M (+$131M)

25% more funds holding

Funds holding: 79 → 99 (+20)

2.26% more ownership

Funds ownership: 99.23% → 101.5% (+2.3%)

Holders
99
Holders Change
+20
Holders Change %
+25.32%
% of All Funds
2.21%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.07%
New
31
Increased
39
Reduced
18
Closed
11
Calls
$288K
Puts
$17K
Net Calls
+$271K
Net Calls Change
-$95K

Top Buyers

1
DCM
Driehaus Capital Management
Illinois
+$18M
2
Neuberger Berman Group
Neuberger Berman Group
New York
+$7.24M
3
Russell Investments Group
Russell Investments Group
United Kingdom
+$6.93M
4
RI
RTW Investments
New York
+$6.89M
5
Primecap Management
Primecap Management
California
+$6.35M

Top Sellers

1
O
OrbiMed
New York
-$8.07M
2
LCS
Levin Capital Strategies
New York
-$4.94M
3
ECM
Endurant Capital Management
California
-$2.54M
4
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
-$717K
5
Barclays
Barclays
United Kingdom
-$394K
Name Holding Trade Value Shares
Change 		Change in
Stake
LCS
1
Levin Capital Strategies
New York
$82.5M -$4.94M -634,723 -6%
Primecap Management
2
Primecap Management
California
$57.5M +$6.35M +815,000 +14%
Neuberger Berman Group
3
Neuberger Berman Group
New York
$47.1M +$7.24M +929,794 +21%
Russell Investments Group
4
Russell Investments Group
United Kingdom
$44.5M +$6.93M +889,727 +21%
DCM
5
Driehaus Capital Management
Illinois
$19.9M +$18M +2,311,112 New
BlackRock
6
BlackRock
New York
$18.4M +$1.39M +178,429 +9%
Vanguard Group
7
Vanguard Group
Pennsylvania
$15.5M +$3M +384,670 +27%
Renaissance Technologies
8
Renaissance Technologies
New York
$10.7M +$686K +88,082 +8%
SSA
9
Schonfeld Strategic Advisors
New York
$8.24M +$4.13M +530,300 +125%
Millennium Management
10
Millennium Management
New York
$8.04M +$4.59M +588,862 +171%
RI
11
RTW Investments
New York
$7.62M +$6.89M +884,235 New
PVI
12
Pura Vida Investments
New York
$5.85M +$3.53M +453,596 +202%
State Street
13
State Street
Massachusetts
$4.9M -$172K -22,023 -4%
GIM
14
Granahan Investment Management
Massachusetts
$4.84M +$4.38M +561,692 New
Acadian Asset Management
15
Acadian Asset Management
Massachusetts
$4.64M +$488K +62,686 +13%
Two Sigma Investments
16
Two Sigma Investments
New York
$4.19M +$1.99M +255,244 +111%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$3.95M +$228K +29,310 +7%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$3.9M +$1.03M +132,549 +41%
HVC
19
Healthcare Value Capital
New Jersey
$3.88M – – –
PAM
20
Panagora Asset Management
Massachusetts
$3.62M +$3.38K +434 +0.1%
ICM
21
Indaba Capital Management
California
$3.45M +$3.12M +400,000 New
KCM
22
Kennedy Capital Management
Missouri
$3.45M +$3.12M +400,000 New
Northern Trust
23
Northern Trust
Illinois
$3.41M -$80.3K -10,314 -3%
Two Sigma Advisers
24
Two Sigma Advisers
New York
$3.17M +$1.93M +247,600 +206%
PCM
25
Perkins Capital Management
Minnesota
$2.8M +$828K +106,300 +49%
1
2 3 4 5

LAB Hedge Fund Activity: Q4 2018 in Review

99 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q4 2018, worth a combined $422M — up 45% from $291M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new LAB positions and 11 closed out — a net gain of 20 holders — while 39 added to existing stakes and 18 trimmed.

The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $18M. The largest seller was OrbiMed, exiting entirely with an estimated $8.07M sold.

  • 99 institutional investors held Standard BioTools (LAB) as of Q4 2018, up from 79 in Q3 2018.
  • Funds reported $422M of Standard BioTools stock for Q4 2018, up 45% quarter-over-quarter.
  • 31 funds opened new Standard BioTools positions in Q4 2018 and 11 closed out, a net change of +20 holders.
  • The largest Standard BioTools buyer in Q4 2018 was Driehaus Capital Management, an estimated $18M added.
  • The largest Standard BioTools seller in Q4 2018 was OrbiMed, an estimated $8.07M sold.

Based on aggregated 13F filings for Q4 2018.